Some studies have reported that the recruitment of an E3 ligase regulates the degradation of FASN in NAFLD [61] and FASN inhibitors have shown therapeutic potential for NAFLD in clinical trials [62, 63]. This evidence concerns the gene FASN and metabolic dysfunction-associated steatotic liver disease.